Skip to Content
Relapsing MS treatment not working? Here’s an option.

Daclizumab Disease Interactions

There are 5 disease interactions with daclizumab:

Major

Daclizumab (Includes Daclizumab) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression

Depression-related events, including suicidal ideation or suicide attempt, have been reported with the use of daclizumab. If severe depression and/or suicidal ideation is present, consider discontinuation of therapy. Caution is recommended when using this agent in patients with previous depressive disorders.

Major

Daclizumab (Includes Daclizumab) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Infections of the upper respiratory tract, urinary tract, and viral infections, sometimes serious, have been reported with the use of daclizumab. It is recommended to avoid daclizumab in patients with a severe active infection. Monitor for signs and symptoms of an infection and consider withholding treatment until the infection resolves.

Major

Daclizumab (Includes Daclizumab) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Daclizumab use can cause life-threatening severe liver injury, including liver failure and autoimmune hepatitis. The use of daclizumab is contraindicated in patients with a history of autoimmune hepatitis or other autoimmune condition involving the liver, and in patients with preexisting liver disease of hepatic impairment, including ALT or AST at least two times the upper limit of normal. Prior to starting therapy with daclizumab, it is recommended to obtain serum transaminases (ALT and AST) and total bilirubin levels in all patients. Continue to monitor levels of transaminase levels and total bilirubin monthly, before each next dose, and follow transaminase levels and total bilirubin monthly for 6 months after the last dose of daclizumab. Treatment modifications are recommended based on serum transaminase and total bilirubin values. If patients develop clinical signs or symptoms suggestive of hepatic dysfunction, immediately discontinue treatment and promptly measure serum transaminases and total bilirubin. Discontinue treatment if autoimmune hepatitis is suspected.

Major

Daclizumab (Includes Daclizumab) ↔ Tuberculosis

Severe Potential Hazard, Moderate plausibility

Applies to: Tuberculosis -- Active, Tuberculosis -- Latent

Tuberculosis has been reported with the use of daclizumab in countries where tuberculosis is endemic. Prior to initiating treatment, it is recommended to evaluate high-risk patients for tuberculosis infection. Patients testing positive for tuberculosis should be treated according to standard medical practice before initiating treatment with daclizumab.

Moderate

Daclizumab (Includes Daclizumab) ↔ Skin Reactions

Moderate Potential Hazard, Moderate plausibility

Applies to: Psoriasis, Eczema

Serious skin reaction, including photosensitivity reactions, have occurred in patients treated with daclizumab. It is recommended to use daclizumab with caution in patients with a history of skin conditions, including eczema or psoriasis, as the use of this agent may exacerbate those conditions. If a patient develops a serious diffuse or inflammatory rash, it is recommended to evaluate the patient before the next dose and to discontinue treatment as appropriate.

daclizumab drug Interactions

There are 108 drug interactions with daclizumab

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide